Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
modified vaccinia Ankara - Bavaria Nordic
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
Modified Vaccinia Ankara–Bavaria Nordic (MVA-BN) is a live, non-replicating, third-generation smallpox and mpox vaccine developed by Bavarian Nordic. It is based on the highly attenuated Modified Vaccinia Ankara (MVA) virus, which has lost the ability to replicate efficiently in mammalian cells. This replication deficiency provides a significantly improved safety profile compared to traditional replicating smallpox vaccines (such as ACAM2000), making it suitable for use in immunocompromised individuals and patients with atopic dermatitis. MVA-BN is approved under the brand names Jynneos in the United States, Imvanex in Europe, and Imvamune in Canada for active immunization against smallpox, mpox, and disease caused by the vaccinia virus.
- Brand names
- ImvamuneImvanexJynneos
- Other names
- Live Modified Vaccinia Virus AnkaraModified Vaccinia AnkaraModified Vaccinia Ankara-Bavarian NordicModified Vaccinia Ankara–Bavaria NordicModified Vaccinia Virus (Ankara-Bavarian Nordic)smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)smallpox and monkeypox vaccine, live, non-replicatingsmallpox and mpox vaccine, live, non-replicating
Beyond the preview
Go deeper on modified vaccinia Ankara - Bavaria Nordic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on modified vaccinia Ankara - Bavaria Nordic.